giant cell glioblastoma (Cancer)
Information
- Disease name
- giant cell glioblastoma
- Disease ID
- DOID:3074
- Description
- "A glioblastoma that is characterized by a prevalence of bizarre, multinucleated giant cells." [url:http\://en.wikipedia.org/wiki/Giant-cell_glioblastoma, url:http\://neuro-oncology.oxfordjournals.org/content/11/6/833.full]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03360708 | Completed | Early Phase 1 | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | November 27, 2013 | June 2, 2021 |
| NCT02366728 | Completed | Phase 2 | DC Migration Study for Newly-Diagnosed GBM | October 12, 2015 | October 31, 2020 |
| NCT02709226 | Completed | Phase 1 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | June 15, 2016 | July 19, 2023 |
| NCT00960492 | Completed | Phase 1 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | September 2009 | October 2013 |
| NCT03027388 | Completed | Phase 2 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | January 9, 2019 | August 31, 2022 |
| NCT01082926 | Completed | Phase 1 | Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | May 2010 | September 2013 |
| NCT01149850 | Completed | Phase 2 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | April 28, 2010 | December 8, 2023 |
| NCT01250470 | Completed | Phase 1 | Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma | September 5, 2012 | May 29, 2014 |
| NCT01480479 | Completed | Phase 3 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | November 2011 | November 2016 |
| NCT01498328 | Completed | Phase 2 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | December 2011 | May 17, 2016 |
| NCT01514201 | Completed | Phase 1/Phase 2 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | February 1, 2012 | March 28, 2018 |
| NCT01609790 | Completed | Phase 2 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | June 4, 2012 | May 20, 2022 |
| NCT01957956 | Completed | Early Phase 1 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | November 11, 2013 | November 16, 2016 |
| NCT01975116 | Completed | Phase 1 | p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors | August 2013 | April 2015 |
| NCT04482933 | Not yet recruiting | Phase 2 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | June 3, 2024 | February 1, 2029 |
| NCT04489420 | Terminated | Phase 1 | Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | October 1, 2020 | August 10, 2021 |
| NCT01095094 | Terminated | Phase 2 | Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | January 2009 | November 2011 |
| NCT01836549 | Terminated | Phase 2 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | March 2013 | April 2016 |
| NCT05218408 | Withdrawn | Phase 1/Phase 2 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | March 8, 2022 | May 2024 |
| NCT03014804 | Withdrawn | Phase 2 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | December 1, 2019 | December 1, 2022 |
| NCT00943462 | Withdrawn | Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM | June 2009 | June 2011 |
- Disase is a (Disease Ontology)
- DOID:3068
- Cross Reference ID (Disease Ontology)
- ICDO:9441/3
- Cross Reference ID (Disease Ontology)
- MESH:D005909
- Cross Reference ID (Disease Ontology)
- NCI:C4325
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:44529004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0334588
- Exact Synonym (Disease Ontology)
- Monstrocellular sarcoma